Endosialin/CD248/TEM1 Antibody (ontuxizumab) [FITC]
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-28072F
Recombinant Monoclonal Antibody
Conjugate
Catalog #
Key Product Details
Species Reactivity
Validated:
Human
Applications
ELISA, Flow Cytometry, Functional
Label
FITC (Excitation = 495 nm, Emission = 519 nm)
Antibody Source
Recombinant Monoclonal Human IgG1 Clone # ontuxizumab
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Summary for Endosialin/CD248/TEM1 Antibody (ontuxizumab) [FITC]
Immunogen
TEM1 / Endosialin / CD248
Clonality
Monoclonal
Host
Human
Isotype
IgG1
Applications for Endosialin/CD248/TEM1 Antibody (ontuxizumab) [FITC]
Application
Recommended Usage
ELISA
Optimal dilutions of this antibody should be experimentally determined.
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Functional
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A purified
Formulation
PBS
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: Endosialin/CD248
Alternate Names
CD164L1, CD248, TEM1
Gene Symbol
CD248
Additional Endosialin/CD248 Products
Product Documents for Endosialin/CD248/TEM1 Antibody (ontuxizumab) [FITC]
Product Specific Notices for Endosialin/CD248/TEM1 Antibody (ontuxizumab) [FITC]
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...